<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <meta name="study:id" content="efficace-pro-cart-gimema">
    <meta name="study:title" content="PF1285 - Patient-Reported Outcomes by CAR-T Product in Aggressive B-Cell Lymphomas">
    <meta name="study:fileName" content="Abstracts/EFFICACE-PRO-CART-GIMEMA-PF1285.html">
    <meta name="study:cancerTypes" content="DLBCL,HGBCL,LBCL,B-NHL">
    <meta name="study:lineOfTherapy" content="2L+">
    <meta name="study:evidenceType" content="Real-world evidence">
    <meta name="study:drugs" content="CAR-T cell therapy,Axicabtagene ciloleucel,Tisagenlecleucel,Brexucabtagene autoleucel,Lisocabtagene maraleucel">

    <title>PF1285: PROs by CAR-T Product in Aggressive B-Cell Lymphomas (Efficace) - SOBI Themed</title>
    <script src="https://cdn.tailwindcss.com"></script>
    <script src="https://d3js.org/d3.v7.min.js"></script>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="abstract_styles.css">
</head>
<body class="abstract-page-body">
    <div class="slide-container">
        <div class="visual-abstract-container">
            <h2 class="visual-abstract-title">Visual Summary: PF1285 - PROs & HRQoL by CAR-T Product in Aggressive B-Cell Lymphomas</h2>
            <div class="visual-abstract-grid">
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path d="M12 6.096c-1.058 0-2.02.468-2.704 1.248-.685.78-.996 1.788-.996 2.856s.311 2.076.996 2.856C9.98 13.84 10.942 14.31 12 14.31s2.02-.468 2.704-1.248.996-1.788.996-2.856-.311-2.076-.996-2.856C14.02 6.564 13.058 6.096 12 6.096zM12 12.81c-.53 0-1.008-.222-1.352-.588-.344-.366-.528-.852-.528-1.422s.184-1.056.528-1.422C10.992 9.012 11.47 8.79 12 8.79s1.008.222 1.352.588.528.852.528 1.422-.184-1.056-.528 1.422C13.008 12.588 12.53 12.81 12 12.81zm6.708 3.672A7.47 7.47 0 0012.024 15c-1.404 0-2.706.39-3.816 1.056A4.476 4.476 0 004.5 19.686V21h15v-1.314a4.476 4.476 0 00-3.792-3.624zM6.024 16.56c.84-.468 1.848-.768 2.904-.924A5.928 5.928 0 0112.024 15a5.928 5.928 0 013.096.636c1.056.156 2.064.456 2.904.924A2.988 2.988 0 0019.5 18.018V19.5h-15v-1.482a2.988 2.988 0 001.524-2.458zM4.5 7.032c0-1.068.312-2.076.996-2.856S7.2 3 8.256 3A7.47 7.47 0 0112.024 1.5c1.404 0 2.706.39 3.816 1.056A4.476 4.476 0 0119.5 6.186V7.5H4.5v-.468zM18 4.56c-.84.468-1.848.768-2.904-.924A5.928 5.928 0 0012.024 6a5.928 5.928 0 00-3.096.636 7.524 7.524 0 00-2.904.924A2.988 2.988 0 014.5 7.482V6H3V4.5A1.5 1.5 0 014.5 3h15A1.5 1.5 0 0121 4.5V6h-1.5v1.482a2.988 2.988 0 01-1.524 2.458L18 4.56z" />
                    </svg>
                    <h4>Population & Aim (N=143)</h4>
                    <p>Aggressive B-Cell Lymphoma Pts. Aim: Describe short-term patient-reported AEs & HRQoL by CAR-T product.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-teal)"> <path fill-rule="evenodd" d="M10.5 3.75a.75.75 0 01.75-.75h1.5a.75.75 0 01.75.75V4.5h3A2.25 2.25 0 0118.75 6.75v1.5a2.25 2.25 0 01-2.25 2.25H15.5V12h1.25a.75.75 0 010 1.5H15.5v1.5h.75a.75.75 0 010 1.5H15.5v1.5H18a.75.75 0 010 1.5h-2.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0V18h-1.5v1.5a.75.75 0 01-1.5 0v-3A2.25 2.25 0 016 14.25v-1.5A2.25 2.25 0 018.25 10.5H9.5V9H8.25A2.25 2.25 0 016 6.75v-1.5A2.25 2.25 0 018.25 3H10.5V3.75zm-1.5 6.75h6V6.75H9V10.5z" clip-rule="evenodd" />
                    </svg>
                    <h4>Methods (Real-World Study)</h4>
                    <p>Multicenter, prospective observational study (GIMEMA). PRO-CTCAE used for AEs at Day +10.</p>
                </div>
                <div class="visual-abstract-item">
                     <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M3.75 3A.75.75 0 003 3.75v16.5a.75.75 0 00.75.75h16.5a.75.75 0 00.75-.75V3.75a.75.75 0 00-.75-.75H3.75zm14.25 1.5H6v13.5h12V4.5zm-10.5 3a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5h9a.75.75 0 000-1.5h-9zm0 3.75a.75.75 0 000 1.5H9a.75.75 0 000-1.5H6z" clip-rule="evenodd" />
                    </svg>
                    <h4>Key Finding</h4>
                    <p><span class="highlight-value">No significant differences</span> in most patient-reported AEs (Day +10) or short-term HRQoL by CAR-T product.</p>
                </div>
                <div class="visual-abstract-item">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 24 24" fill="var(--sobi-orange)"> <path fill-rule="evenodd" d="M12 2.25c-5.385 0-9.75 4.365-9.75 9.75s4.365 9.75 9.75 9.75 9.75-4.365 9.75-9.75S17.385 2.25 12 2.25zm-.092 14.444a.75.75 0 01-.092 0l-3.75-3.75a.75.75 0 111.06-1.06L12 14.813l3.182-3.182a.75.75 0 111.06 1.06l-3.75 3.75a.75.75 0 01-.53.22z" clip-rule="evenodd" />
                    </svg>
                    <h4>Conclusion</h4>
                    <p>Type of CAR T-cell product is not associated with short-term HRQoL. Further research needed.</p>
                </div>
            </div>
        </div>

        <div class="text-center mb-8">
            <h1 class="abstract-header-title">PF1285 - Exploring short-term patient-reported adverse events (AEs) and health-related quality of life (HRQoL) by CAR T-cell product in patients with aggressive B-cell lymphomas: Evidence from a real-world study by the GIMEMA</h1>
            <p class="abstract-sub-header">Fabio Efficace, A. Ghisolfi, L. Bracci, et al.</p>
            <p class="abstract-meta-info mt-2">EHA 2025 Congress | Abstract #PF1285 | Publication Only</p>
        </div>

        <div class="grid md:grid-cols-2 gap-x-8 gap-y-6">
            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Background</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Chimeric antigen receptor (CAR) T-cell therapy has markedly transformed care for patients with aggressive B-cell lymphomas.</li>
                        <li>However, very limited evidence is available on patient-reported AEs and HRQoL.</li>
                    </ul>
                </div>

                <div class="abstract-card">
                    <h2 class="abstract-section-title">Aims</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>To describe the prevalence of short-term (day+10) patient-reported AEs by the type of CAR T-cell product in patients treated in real-life.</li>
                        <li>To explore the prognostic value of the CAR T-cell product for short-term health-related quality of life (HRQoL).</li>
                    </ul>
                </div>
                
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Methods & Study Design</h2>
                    <ul class="list-disc list-inside text-sm space-y-1 mb-3 pl-2">
                        <li>Study Type: Multicenter, prospective observational study (GIMEMA).</li>
                        <li>Patient Population: Adults with aggressive B-cell lymphomas scheduled to undergo CAR T-cell therapy.</li>
                        <li>Data Collection:
                            <ul class="list-circle list-inside ml-4">
                                <li>Symptomatic AEs assessed on day +10 post-infusion using 20 items from the NCI PRO-CTCAE Item Library (items included difficulty swallowing, decreased appetite, nausea, diarrhea, swelling, hair loss, sleepiness, concentration, memory, general pain, headache, muscle pain, joint pain, insomnia, fatigue, anxious, discouragement, sad, and chills).</li>
                                <li>HRQoL assessed with short-term (month 1) global health status/QoL scale of the EORTC QLQ-C30.</li>
                            </ul>
                        </li>
                        <li>Analysis: Descriptive analyses for AEs. Multivariable linear regression to assess whether CAR T-cell product was independently associated with HRQoL, adjusting for baseline HRQoL, age, gender, ECOG PS, time from diagnosis to infusion, IELSG, comorbidities, etc.</li>
                    </ul>
                </div>

                 <div class="abstract-card">
                    <h2 class="abstract-section-title">Patient Characteristics & CAR-T Products (N=143)</h2>
                    <div class="table-container">
                        <table>
                            <thead>
                                <tr><th>Characteristic</th><th>Value</th></tr>
                            </thead>
                            <tbody>
                                <tr><td>Eligible Patients</td><td>143</td></tr>
                                <tr><td>Median Age, years (range)</td><td>57 (19-75)</td></tr>
                                <tr><td>Male gender, n (%)</td><td>98 (68.5)</td></tr>
                                <tr><td>ECOG PS 0, n (%)</td><td>77 (53.8)</td></tr>
                                <tr><td>Stage IV, n (%)</td><td>91 (63.6)</td></tr>
                                <tr><td>Time from Dx to Infusion, months (median)</td><td>25</td></tr>
                                <tr><td class="font-semibold pt-3">CAR T-cell Product Received, n</td><td></td></tr>
                                <tr><td class="pl-6">Axicabtagene ciloleucel (axi-cel)</td><td>86</td></tr>
                                <tr><td class="pl-6">Tisagenlecleucel (tisa-cel)</td><td>34</td></tr>
                                <tr><td class="pl-6">Brexucabtagene autoleucel (brexu-cel) & Lisocabtagene maraleucel (liso-cel)</td><td>23</td></tr>
                            </tbody>
                        </table>
                    </div>
                </div>
            </div>

            <div>
                <div class="abstract-card">
                    <h2 class="abstract-section-title">Results</h2>
                    <p class="text-sm font-semibold mt-1 mb-1">Patient-Reported Adverse Events (Day+10):</p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Patients infused with axi-cel were younger (median age 53y vs 64y) and had a better ECOG-PS.</li>
                        <li>No significant differences in AE prevalence based on CAR-T product, except for 'feeling sad' (p=0.03), which was highest in the brexu-cel and liso-cel group.</li>
                    </ul>
                    <p class="text-sm font-semibold mt-3 mb-1">Health-Related Quality of Life (Month 1):</p>
                    <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                        <li>Multivariable analyses showed the type of CAR T-cell product was not a significant prognostic factor for short-term HRQoL.</li>
                        <li>Only baseline HRQoL (p<0.001) and IELSG score (p=0.03) were found to be independent prognostic factors for month 1 HRQoL.</li>
                    </ul>
                     <div class="abstract-card mt-4">
                        <h3 class="text-md font-semibold mb-2 text-center" style="color: var(--sobi-dark-blue);">Figure: Prevalence of Patient-Reported AEs at Day +10</h3>
                        <p class="text-xs text-center mt-2 italic">(The figures from the poster show prevalence of General, GI, and Neuropsychiatric AEs, with "Feeling Sad" being the only statistically significant difference among groups. The overall visual message is of broad similarity across products for most symptoms.)</p>
                        <div class="km-plot-container zoomable-image-container">
                             <img src="https://storage.googleapis.com/generativeai-downloads/ESH2025/PF1285_Figures.png" alt="Figure 1: Day+10 General AEs, Figure 2: Day+10 GI/Neuropsychiatric AEs" class="zoomable-image" onerror="this.onerror=null; this.src='https://placehold.co/600x400/E0F2F7/0A2F5C?text=AE+Charts+Not+Available';">
                        </div>
                    </div>
                </div>
            </div>
        </div>

        <div class="abstract-card mt-6">
            <h2 class="abstract-section-title">Summary & Conclusion</h2>
            <ul class="list-disc list-inside text-sm space-y-1 pl-2">
                <li>This real-world study provides insights into the short-term patient-reported AEs and HRQoL across different CAR T-cell products.</li>
                <li>Findings may help better understand the impact of CAR T-cell products on symptom prevalence and suggest that the type of CAR T-cell product is not associated with short-term HRQoL.</li>
                <li>Further research is warranted to elucidate factors predicting patient-reported outcomes and HRQoL.</li>
            </ul>
        </div>

        <div class="abstract-card mt-6 abbreviations-list">
            <h2 class="abstract-section-title">Abbreviations</h2>
            <p>AE, Adverse Event; ASCT, Autologous Stem Cell Transplantation; CAR-T, Chimeric Antigen Receptor T-cell; CR, Complete Remission; Dx, Diagnosis; ECOG-PS, Eastern Cooperative Oncology Group Performance Status; EORTC QLQ-C30, European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire Core 30; GIMEMA, Gruppo Italiano Malattie EMatologiche dell’Adulto; GI, Gastrointestinal; HRQoL, Health-Related Quality of Life; IELSG, International Extranodal Lymphoma Study Group; NCI PRO-CTCAE, National Cancer Institute Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events; ORR, Overall Response Rate; OS, Overall Survival; PFS, Progression-Free Survival; PR, Partial Remission; PRO, Patient-Reported Outcome; Pts, Patients; QoL, Quality of Life; R/R, Relapsed or Refractory.</p>
        </div>

        <div class="abstract-card mt-6 reference-section">
            <h2 class="abstract-section-title">
                Reference
                <button id="copyReferenceBtn" class="copy-reference-button" title="Copy Reference">
                    <svg xmlns="http://www.w3.org/2000/svg" viewBox="0 0 20 20" fill="currentColor">
                        <path d="M7 3.5A1.5 1.5 0 018.5 2h3.879a1.5 1.5 0 011.06.44l3.122 3.121A1.5 1.5 0 0117 6.621V16.5a1.5 1.5 0 01-1.5 1.5h-7A1.5 1.5 0 017 16.5v-13z" />
                        <path d="M4.5 6A1.5 1.5 0 003 7.5v10A1.5 1.5 0 004.5 19h7a1.5 1.5 0 001.5-1.5v-2.5a.75.75 0 00-1.5 0v2.5a.5.5 0 01-.5.5h-7a.5.5 0 01-.5-.5v-10a.5.5 0 01.5-.5h2.5a.75.75 0 000-1.5H4.5z" />
                    </svg>
                    Copy
                </button>
            </h2>
            <p id="referenceSectionContent">
                Efficace F, Ghisolfi A, Bracci L, et al. Exploring short-term patient-reported adverse events (aes) and health-related quality of life (hrqol) by car t-cell product in patients with aggressive b-cell lymphomas: Evidence from a real-world study by the gimema. Abstract #PF1285 presented at the European Hematology Association (EHA) Congress. 12–15 June 2025, Milan, Italy.
            </p>
        </div>

        <div class="abstract-footer-info">
            <p>EHA 2025 Congress | Abstract #PF1285 | Presentation: 06/13/2025</p>
            <p>For Research & Informational Purposes Only.</p>
        </div>
    </div>

    <script defer src="abstract_features.js"></script>
</body>
</html>